Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lartesertib monotherapy in advanced solid tumors
NCT04882917Phase 1Completed
- Sponsor
- EMD Serono
- Start
- May 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of lartesertib in solid tumor (advanced stage) (4 arms), sponsored by EMD Serono. Primary endpoints: Dose Limiting Toxicities, Treatment-emergent Adverse Events and 3 more. Started May 2021; status: completed.
02
Drugs
lartesertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04882917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882917.